WEST HAVEN, Conn.--(BUSINESS WIRE)--
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), announced today that its stock began trading today on the NYSE MKT National Exchange under its original symbol, NNVC.
In another Company news, our CEO, Eugene Seymour, MD, MPH, is invited to speak at the Duke University Fuqua School of Business today afternoon. His talk will focus on policies that can help accelerate the development of pharmaceuticals against diseases that pharma companies would otherwise not have much interest in, or “orphan drug” development.
Dr. Seymour will discuss the economic incentives associated with orphan drug development, focusing on the importance of the Priority Review Voucher (PRV), and their relevance to the decision-making process of both small and large pharmaceutical and biotech companies. He will illustrate his arguments using the example of DengueCide™, the Company’s nanoviricide drug against dengue, that has been designated an “orphan drug” by the US FDA.
As noted in Monday’s press release, Scott Cutler, Executive Vice President, Head of Global listing, NYSE Eurotext, made the following statement about the Company and the new listing: “We congratulate NanoViricides on their listing with NYSE MKT. Our community ranges across a variety of industries and it is always exciting for a biotech company like NanoViricides to benefit from our platform and further support their research and development.”
The concept of the PRV was initially developed by three professors, David Ridley, Jeff Moe and Henry Grabowski at the Fuqua School of Business of the Duke University. Dr. Ridley invited Dr. Seymour to speak on the importance of economic incentives to help innovative pharmaceutical companies attach higher priorities to drug development programs against “orphan” diseases.
The Priority Review Voucher concept that the professors developed was embraced by the US FDA. Currently, the US FDA’s list of diseases for which no adequate therapy exists that are eligible for a PRV contains about 16 diseases. Dengue is at present the only viral disease on the list. The existence of the PRV was an important factor in the Company’s decision to assign a high priority to its dengue drug development program.
NYSE MKT is considered a premier US equities market for listing and trading of small growth companies. NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.
NanoViricides, Inc. currently has six drug development pipeline indications and several research programs. The Company is advancing both an injectable drug and an oral drug against Influenzas in IND-enabling studies in its FluCide™ program. The oral FluCide drug is being developed for out-patient influenza cases. The injectable FluCide is being developed for the seriously ill, hospitalized patients with influenza-like illness. Both of these drugs are broad-spectrum, i.e. they are expected to work against most if not all influenza A viruses. The Company believes so because the virus-binding ligand in these drugs mimics the component of the cell receptor known to be used by all influenza viruses in order to gain entry into the cell. Both of these anti-influenza drugs may also be useful for prophylaxis, such as for the protection of health care workers. In addition, the Company has developed several other highly effective nanoviricides. These include HIVCide™, HerpiCide™, DengueCide™, and a broad-spectrum nanoviricide eye drop formulation for the treatment of epidemic keratoconjunctivitis (EKC), a viral infection of the eye. The Company’s drug programs are based on the Company’s patented “nanoviricide®” platform technology that enables specifically targeting a particular type of virus with a novel mechanism of action. In addition, the Company’s other research and development programs include (a) broad-spectrum nanoviricides against a number of Neglected Tropical Diseases, and (b) its novel ADIF™ ( “Accurate Drug In Field”™ ) technologies which promise a way to attack novel viruses, whether man-made (bioterrorism) or natural (such as SARS), before they can cause a pandemic.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing broad-spectrum drugs against a number of viral diseases. The Company’s development candidates include an anti-influenza injectable drug and an anti-influenza oral drug; both expected to be effective against most types of influenza viruses including H1N1 swine flu, H5N1 bird flu, seasonal Influenzas, and possibly the recent threat of novel H7N9 influenza A virus. In addition, the Company is also developing drugs against HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, and Dengue viruses. The Company’s research programs include Hepatitis C, Rabies, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the Company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
- Health Care Industry
- Pharmaceuticals & Drug Trials
- NYSE Euronext
Amanda Schuon, 310-550-7200